Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.41 |
| ▸ | KDR | P35968 | 7/20 | 0.39 |
| ▸ | EGFR | P00533 | 4/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8965653 | 0.95 | KDR (0.41) | PIK3CAKDREGFRCSNK1DKDM4E | |
| SCHEMBL8966365 | 0.93 | PIK3CA (0.41) | PIK3CAKDRCSNK1DPIK3CDPIK3CG | |
| SCHEMBL8965972 | 0.93 | PIK3CA (0.46) | PIK3CAKDRCSNK1DPIK3CDPIK3CG | |
| SCHEMBL8965644 | 0.93 | PIK3CA (0.42) | PIK3CAKDRCSNK1DKDM4ERIPK1 | |
| SCHEMBL8965590 | 0.90 | PIK3CA (0.45) | PIK3CAKDRCSNK1DPIK3CDPIK3CG | |
| SCHEMBL8966177 | 0.90 | PIK3CA (0.40) | PIK3CAKDRCSNK1DPIK3CDPIK3CG | |
| SCHEMBL8965601 | 0.87 | RIPK1 (0.42) | PIK3CAKDRCSNK1DRIPK1SMN1; SMN2 | |
| SCHEMBL8965523 | 0.86 | PIK3CA (0.47) | PIK3CAKDRCSNK1DPIK3CDPIK3CG | |
| SCHEMBL8965909 | 0.86 | PIK3CA (0.42) | PIK3CAKDRPIK3CDPIK3CGRIPK1 | |
| SCHEMBL8965694 | 0.86 | PIK3CA (0.39) | PIK3CAKDRCSNK1DPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0305093-A1 | Imidazo(1,2-b)pyridazine derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-03-01 | — | — | EP | claimed |
| US-5538970-A | Treatment of cancer with imidazo-1,2-pyridazin compounds | GLAXO WELLCOME INC. (US) | 1996-07-23 | — | — | US | disclosed |
| US-5447956-A | Anticarcinogenic agents | BURROUGHS WELLCOME CO. (US) | 1995-09-05 | — | — | US | disclosed |
| US-5380759-A | Methyl N-[6-(3,4,5-trimethoxybenzloxy)imidazo[1,2-b]pyridazin-2-zyl]carbamate used to treat leukemia | BURROUGHS WELLCOME CO. (US) | 1995-01-10 | — | — | US | disclosed |
| US-5371219-A | Antitumor agents | BURROUGHS WELLCOME CO. (US) | 1994-12-06 | — | — | US | disclosed |
| US-5091531-A | Antitumor agents | BURROUGHS WELLCOME CO. (US) | 1992-02-25 | — | — | US | disclosed |
| EP-0305093-A1 | Imidazo(1,2-b)pyridazine derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-03-01 | — | — | EP | disclosed |